AI Article Synopsis
- * Developing selective Akt inhibitors has been difficult, but recent clinical trials of drugs like Ipatasertib and Capivasertib, used alongside androgen deprivation therapies, have shown positive results in patients with advanced prostate cancer and PTEN loss.
- * Current research is focused on evaluating multiple Akt inhibitors in various combinations and at different disease stages to better understand their effectiveness in treating prostate cancer.
Article Abstract
Deregulation of the PI3K-Akt-mTOR pathway plays a critical role in the development and progression of many cancers. In prostate cancer, evidence suggests that it is mainly driven by PTEN loss of function. For many years, the development of selective Akt inhibitors has been challenging. In recent phase II and III clinical trials, Ipatasertib and Capivasertib associated with androgen deprivation therapies showed promising outcomes in patients with metastatic castration-resistant prostate cancer and PTEN-loss. Ongoing trials are currently assessing several Akt inhibitors in prostate cancer with different combinations, at different stages of the disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745410 | PMC |
| http://dx.doi.org/10.3390/jcm11010160 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!